Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Department of Pathology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
World J Gastroenterol. 2020 May 14;26(18):2126-2137. doi: 10.3748/wjg.v26.i18.2126.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a dismal prognosis, especially when diagnosed at advanced stages. Annexin A2 (ANXA2), is found to promote cancer progression and therapeutic resistance. However, the underlining mechanisms of ANXA2 in immune escape of HCC remain poorly understood up to now. Herein, we summarized the molecular function of ANXA2 in HCC and its relationship with prognosis. Furthermore, we tentatively elucidated the underlying mechanism of ANXA2 immune escape of HCC by upregulating the proportion of regulatory T cells and the expression of several inhibitory molecules, and by downregulating the proportion of natural killer cells and dendritic cells and the expression of several inhibitory molecules or effector molecules. We expect a lot of in-depth studies to further reveal the underlying mechanism of ANXA2 in immune escape of HCC in the future.
肝细胞癌 (HCC) 是最常见的原发性肝癌，预后较差，尤其是在晚期诊断时。膜联蛋白 A2 (ANXA2) 被发现可促进癌症进展和治疗耐药性。然而，到目前为止，ANXA2 在 HCC 免疫逃逸中的潜在机制仍知之甚少。在此，我们总结了 ANXA2 在 HCC 中的分子功能及其与预后的关系。此外，我们通过上调调节性 T 细胞的比例和几种抑制性分子的表达，下调自然杀伤细胞和树突状细胞的比例以及几种抑制性分子或效应分子的表达，推测了 ANXA2 逃避 HCC 免疫的潜在机制。我们希望未来有更多的深入研究来进一步揭示 ANXA2 在 HCC 免疫逃逸中的潜在机制。
